0001104659-23-071204.txt : 20230614 0001104659-23-071204.hdr.sgml : 20230614 20230614161617 ACCESSION NUMBER: 0001104659-23-071204 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230609 FILED AS OF DATE: 20230614 DATE AS OF CHANGE: 20230614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dudley Robert Michael CENTRAL INDEX KEY: 0001854161 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40363 FILM NUMBER: 231014316 MAIL ADDRESS: STREET 1: C/O TRANSCODE THERAPEUTICS STREET 2: 6 LIBERTY SQUARE #2382 CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Transcode Therapeutics, Inc. CENTRAL INDEX KEY: 0001829635 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811065054 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-301-6857 MAIL ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 4/A 1 tm2318742-1_4aseq1.xml OWNERSHIP DOCUMENT X0407 4/A 2023-06-09 2023-06-13 0 0001829635 Transcode Therapeutics, Inc. RNAZ 0001854161 Dudley Robert Michael C/O TRANSCODE THERAPEUTICS, INC. 6 LIBERTY SQUARE, #2382 BOSTON MA 02109 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-06-09 4 P 0 19000 2.76 A 61155 D Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price. This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023. /s/ Thomas A. Fitzgerald, as Attorney-in-Fact 2023-06-14